ClinicalTrials.gg
Active, not recruitingNCT06157567Updated Nov 2, 2026

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

An interventional study of Profound Matrix in Skin Laxity, Wrinkle and Skin Condition, sponsored by Candela Corporation. Active, not recruiting at 6 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Candela Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2022, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Planned enrollment
18th of 172
500 · median 99
Started
2022
with 17 others
No phase
33 of 202
6 open now
Primary completion
2027-05
later than 23 of 48 live
Registered
163rd of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 18th largest by planned enrollment of the 172 interventional ones that give a count, is one of 18 that started in 2022, is one of 33 with no phase, reaches primary completion later than 23 of the 48 other live ones, and was the 163rd registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a non-randomized, multi-center, open-label clinical trial evaluating clinical feasibility treatments with the Profound Matrix system.

Read the detailed description

The Profound Matrix system is a multipurpose (3-in-1) radiofrequency (RF) platform. The clinical study is to evaluate the safety and performance of the Profound Matrix system with Sublime applicator, RF applicator and Matrix Pro applicator for aesthetic treatments including its cleared indications of wrinkles, acne scars, striae, and electrocoagulation and hemostasis. The Sublime and Sublative RF applicators are equivalent to those on the European conformity (CE) marked eLos, eTwo, eMatrix device family. The Matrix Pro applicator utilizes micro-needling technology and is new feature of the Profound Matrix system. The Profound Matrix system, including the Matrix Pro applicator are currently cleared for use in the US under FDA 510k K211217. This study aims to evaluate additional indications for treatment through the electrocoagulation and hemostasis mechanism of action for dermal remodeling and improvement in skin conditions to provide study subjects with a safe and effective alternative treatment that can be performed with minimal risks and decreased downtime. Eligible subjects would be healthy adult volunteers between 18 to 75 years of age seeking clinical treatment for indications as listed above. The research is sponsored by Candela Corporation and planned to be conducted at up to 20 sites globally. From the first subject enrollment to the last subject follow-up, the expected total duration is up to 5 years across all sites. The participants will undergo informed consent, screening and enrollment, treatments for the indication to be treated, and follow-up visits at no cost. The data from this research will assist Candela in optimizing treatment parameters, treatment guidelines, providing input to clinical education and marketing material, and support the research and development of micro-needling technology alongside energy-based devices.

03

Conditions studied

  • Skin Laxity
  • Wrinkle
  • Skin Condition

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female and male subjects between 18 to 75 years of age with Fitzpatrick Skin Type I - VI.
  2. Willing to receive Profound Matrix treatments with any of the following applicators: Sublime, Sublative RF, and/or Matrix Pro applicator
  3. Able and willing to comply with the treatment/follow-up schedule and comply with all study (protocol) requirements.
  4. Willing to provide signed, to participate in the study
  5. Willing to have photographs and images taken of the treated areas to be used in evaluations, publications, presentations, and marketing materials (Subject identity will be masked).

Exclusion criteria

Exclusion Criteria:

Any of the following will exclude the subject from the study:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months prior to enrollment into the study, and/or breast feeding
  2. Pacemaker or internal defibrillator or any active electrical implant anywhere in the body
  3. Superficial metal or other implants in the treatment area, except superficial dental implants, unless these implants can be removed or covered with rolled gauze during treatment
  4. Skin cancer in the treatment area or history of melanoma
  5. History of current cancer and subject has undergone chemotherapy within the last 12 months
  6. Severe concurrent conditions, such as cardiac disorders
  7. Impaired immune system or use of medications
  8. Herpes Simplex Virus (HSV) in the intended treatment area unless treated following a prophylactic regimen
  9. Poorly controlled endocrine disorders such as poorly controlled diabetes
  10. Active skin condition in the treatment area such as skin infection, sores, psoriasis, eczema, rash, or open wounds
  11. History of abnormal wound healing, keloid, or hypertrophic scar formation, as well as very thin or fragile skin
  12. History of collagen vascular disease or vasculitic disorders
  13. Known allergy to medication to be used during treatments such as allergy to topical anesthetic (e.g. lidocaine)
  14. History of systemic therapy in past six months
  15. Tattoos or permanent makeup in the intended treatment area
  16. Excessively tanned skin
  17. Facelift in the last 12 months
  18. Aesthetics treatments/procedures (e.g. facial resurfacing and deep chemical peeling) within the last 4 months within the intended treatment area
  19. Neuromodulator injections (e.g. Botox®), collagen, non-permanent dermal filler, or fat injections or other methods of augmentation with injected bio-material in the treated area within the last 3 months
  20. Permanent synthetic fillers (e.g. silicone) in the treatment area
  21. Absorbable facial threads within the last 1 year or non-absorbable facial threads within the intended treatment area
  22. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements or is otherwise unsuitable for the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Study subjects may be treated with any of the Profound Matrix applicators: Sublime, Sublative RF and/or Matrix Pro. Treatments may include combination of applicators or additional commercial devices per PI discretion.

    Device: Profound Matrix

Interventions

  • DeviceProfound Matrix

    Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

06

What researchers measure

Primary outcomes

  1. Standardized Clinical Photography

    Clinical photography will be taken of treated areas at baseline prior to treatment and all treatment and follow-up visits.

    Time frame: From subject enrollment to completion of 3-month follow-up visit, up to 32 weeks.

  2. Numerical Rating Scale (NRS)

    Subject assessment of treatment discomfort/pain immediately post-treatment via Numerical Rating Scale (NRS). Subjects will be presented a horizontal line scale and asked to make a mark along the scale. Subjects will be asked to rate pain from 0 to 10, with 0 equaling no pain and 10 equaling the worst possible pain. A number is obtained by measuring up to the point the participant has indicated.

    Time frame: From the first treatment to the third treatment, up to 16 weeks.

  3. Post-treatment Assessment Severity Scale

    Skin responses including edema, erythema, pinpoint bleeding, purpura/ecchymosis, petechiae, and microscopic epithelial necrotic debris (MENDs) will be assessed immediately after treatment with a post-treatment assessment severity scale: grade 1 means absent, grade 2 means mild, grade 3 means moderate, and grade 3 means severe.

    Time frame: From the first treatment to the third treatment, up to 16 weeks.

  4. Investigator Global Aesthetic Improvement Scale (IGAIS)

    Investigator Global Aesthetic Improvement Scale (IGAIS) will be assessed at each follow-up visit with score -1 to 3 and corresponding ratings: -1 means worse, 0 means no change, 1 means improved, 2 means much improved, 3 means very much improved.

    Time frame: At 1-month follow-up and 3-month follow-up, up to 14 weeks.

  5. Subject Satisfaction Scale

    Subject satisfaction rating of improvement in indication will be obtained at each follow-up visit. The subject satisfaction scale scores from -2 to 2 with corresponding improvement rate: -2 means very dissatisfied, -1 means somewhat satisfied, 0 means neutral, 1 means somewhat satisfied, 2 means very satisfied.

    Time frame: At 1-month follow-up and 3-month follow-up, up to 14 weeks.

07

Study locations

6 sites
  • Center for Morden Aesthetic Medicine
    Jacksonville, Florida 32207, United States
  • Candela Institue for Excellence
    Marlborough, Massachusetts 01752, United States
  • Concierge Medical Arts
    Fayetteville, North Carolina 28306, United States
  • Gerrish MedEsthetics
    Vienna, Virginia 22180, United States
  • Waterfront Skin and Laser
    Vancouver, Canada
  • Candela European Institue of Excellence
    Madrid, 28830, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 53 industry-sponsored interventional studies with no phase under Skin Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 60 months is above that.

Counting every sponsor, half of 95 studies reached it within 7 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Dec 6, 2023
StartActual
May 24, 2022
Primary completionEst.
May 24, 2027
CompletionEst.
May 24, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06157567
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
May 24, 2022
Primary completion
May 24, 2027 (estimated)
Completion
May 24, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Konika Schallen, MD
principal investigator · Candela Institue for Exellence

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion